Heteroaromatic compounds and their use as dopamine D1 ligands

US9868744B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• David Lawrence Firman Gray · Groton, US
• Lei Zhang · Beijing, CN
• Jennifer Elizabeth Davoren · Cambridge, US
• Amy Beth Dounay · Colorado Springs, US
• Ivan Viktorovich Efremov · Sharon, US
• Chewah Lee · Wallingford, US
• Scot Richard Mente · Arlington, US
• Steven Victor O'Neil · East Lyme, US
• Bruce N. Rogers · Belmont, US
• Chakrapani Subramanyam · South Glastonbury, US

Key dates

• Filing date: Apr 13, 2015
• Grant date: Jan 16, 2018
• Expiry date: Apr 13, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.